Clinical trials: Vascular Dementia (VaD)

Vascular Dementia

Local Study of Akatinol Memantine in VaD in Russia

• Completed
• Age: 50 to 85 years
• Phase 3

The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from moderate and moderately severe vascular dementia.

Trial name

MIND (NCT03986424)

Testing

Akatinol Memantine 20 mg, Akatinol Memantine 10 mg

Where

4 sites in Russia

Volunteers

130 people

Sponsor

Merz Pharmaceuticals GmbH